Paul Chapman

11PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy, Hannah L Kalvin, Fiona D Ehrich

|Nov 06, 2023
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.

Paul B Chapman, Mark Klang, Michael A Postow

|Jun 03, 2023
Management of immune-related cutaneous adverse events with dupilumab.

Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll

|Feb 06, 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.

Thomas M Atkinson, Jennifer L Hay, Soo Young Kim

|Jan 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.

Claire F Friedman, Christine Spencer, Christopher R Cabanski

|Jan 14, 2022
PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.

Margaret K Callahan, Paul B Chapman

Pageof 2

Frequent Collaborators

6 joint publications

Michael Postow

6 joint publications

Alexander Shoushtari

4 joint publications

Jedd D Wolchok

4 joint publications

Allison S Betof